Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

E0550000

Epirubicin hydrochloride

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

4′-Epidoxorubicin hydrochloride, Epidoxorubicin hydrochloride

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C27H29NO11 · HCl
Numero CAS:
56390-09-1
Peso molecolare:
579.98
Numero MDL:
MFCD00941448
Codice UNSPSC:
41116107
ID PubChem:
329798975
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

epirubicin

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

Cl.COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO

InChI

1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22-,27-;/m0./s1
MWWSFMDVAYGXBV-FGBSZODSSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Epirubicin hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Cell-permeable anthracycline antitumor antibiotic. Antineoplastic. A stereoisomer of doxorubicin that exhibits reduced cardiotoxicity. Its antitumor actions are mediated by targeting topoisomerase II.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Pittogrammi

Health hazardExclamation mark
GHS08,GHS07

Avvertenze

Danger

Indicazioni di pericolo

H302,H340,H350,H360

Classi di pericolo

Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Paclitaxel European Pharmacopoeia (EP) Reference Standard

Y0000698

Paclitaxel

5-Fluorouracil analytical standard

Supelco

03738

5-Fluorouracil

USP

USP

1225758

Doxorubicinone

Cisplatin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1624

Cisplatin

Etoposide synthetic, 95.0-105.0%, powder

Sigma-Aldrich

E1383

Etoposide

Metformin hydrochloride Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1084

Metformin hydrochloride

Doxorubicina 98.0-102.0% (HPLC)

Sigma-Aldrich

D1515

Doxorubicina

Quercetin ≥95% (HPLC), solid

Sigma-Aldrich

Q4951

Quercetin

D Groheux et al.
British journal of cancer, 109(5), 1157-1164 (2013-08-15)
Pathologic complete response (pCR) to neoadjuvant treatment (NAT) is associated with improved survival of patients with HER2+ breast cancer. We investigated the ability of interim positron emission tomography (PET) regarding early prediction of pathology outcomes. During 61 months, consecutive patients
Chikako Suzuki et al.
Medical oncology (Northwood, London, England), 30(1), 415-415 (2013-01-17)
The aim of this was to determine whether the change of size observed at the first response evaluation after initiation of first-line combination chemotherapy correlates with overall survival (OS) in patients with metastatic breast cancer (MBC). The change in size
Sarah N Hamilton et al.
International journal of radiation oncology, biology, physics, 87(4), 719-725 (2013-09-05)
To review the treatment and outcomes of patients with primary cutaneous B-cell lymphoma (CBCL). Clinical characteristics, treatment, and outcomes were analyzed for all patients referred to our institution from 1981 through 2011 with primary CBCL without extracutaneous or distant nodal
Gunter von Minckwitz et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(28), 3531-3539 (2013-08-28)
Bisphosphonates prevent skeletal-related events in patients with metastatic breast cancer. Their effect in early breast cancer is controversial. Ibandronate is an orally and intravenously available amino-bisphosphonate with a favorable toxicity profile. It therefore qualifies as potential agent for adjuvant use.
Yi Zhang et al.
Toxicology letters, 222(1), 1-9 (2013-07-13)
Epirubicin is widely used in osteosarcoma chemotherapy. Growing evidence indicates that the microRNA (miRNA) expression levels which are induced by chemotherapeutic agents play an important role in osteosarcoma development and progression. In this study we investigate the alterations of miRNA
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.